ES2531018T3 - Vacuna contra la tuberculosis y método de uso de la misma - Google Patents

Vacuna contra la tuberculosis y método de uso de la misma Download PDF

Info

Publication number
ES2531018T3
ES2531018T3 ES08745627T ES08745627T ES2531018T3 ES 2531018 T3 ES2531018 T3 ES 2531018T3 ES 08745627 T ES08745627 T ES 08745627T ES 08745627 T ES08745627 T ES 08745627T ES 2531018 T3 ES2531018 T3 ES 2531018T3
Authority
ES
Spain
Prior art keywords
tuberculosis vaccine
composition
inactivated
host
mucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08745627T
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Lighter
Jason Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mico Bio Inc
Original Assignee
Mico Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mico Bio Inc filed Critical Mico Bio Inc
Application granted granted Critical
Publication of ES2531018T3 publication Critical patent/ES2531018T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08745627T 2007-04-12 2008-04-11 Vacuna contra la tuberculosis y método de uso de la misma Active ES2531018T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
PCT/US2008/060065 WO2008128065A2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Publications (1)

Publication Number Publication Date
ES2531018T3 true ES2531018T3 (es) 2015-03-09

Family

ID=39523390

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08745627T Active ES2531018T3 (es) 2007-04-12 2008-04-11 Vacuna contra la tuberculosis y método de uso de la misma

Country Status (14)

Country Link
US (3) US8394389B2 (cg-RX-API-DMAC7.html)
EP (1) EP2144626B8 (cg-RX-API-DMAC7.html)
JP (2) JP5713672B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008240181B2 (cg-RX-API-DMAC7.html)
CA (1) CA2682870C (cg-RX-API-DMAC7.html)
CY (1) CY1117290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2144626T3 (cg-RX-API-DMAC7.html)
ES (1) ES2531018T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150177T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024427T2 (cg-RX-API-DMAC7.html)
PL (1) PL2144626T3 (cg-RX-API-DMAC7.html)
PT (1) PT2144626E (cg-RX-API-DMAC7.html)
SI (1) SI2144626T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008128065A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128065A2 (en) 2007-04-12 2008-10-23 Jennifer Lighter Tuberculosis vaccine and method of using same
CN105709221B (zh) 2011-04-06 2020-11-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
JP2014512388A (ja) * 2011-04-20 2014-05-22 マイコ・バイオ，インコーポレーテッド 免疫反応を増進するための組成物および方法
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
WO2014001571A1 (en) * 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) * 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
CN1612753A (zh) 2001-11-14 2005-05-04 诺瓦瓦克斯有限公司 分枝杆菌疫苗
KR20050008453A (ko) * 2002-03-08 2005-01-21 바쿠레시 마파탈 카마르 결핵 관리에 유용한 약제학적 조성물의 제조방법
JP5219808B2 (ja) * 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
WO2008128065A2 (en) 2007-04-12 2008-10-23 Jennifer Lighter Tuberculosis vaccine and method of using same

Also Published As

Publication number Publication date
JP2015038130A (ja) 2015-02-26
US20150258187A1 (en) 2015-09-17
AU2008240181B2 (en) 2014-01-09
EP2144626A2 (en) 2010-01-20
US8394389B2 (en) 2013-03-12
JP5713672B2 (ja) 2015-05-07
DK2144626T3 (en) 2015-02-09
SI2144626T1 (sl) 2015-04-30
US20100112007A1 (en) 2010-05-06
PT2144626E (pt) 2015-03-03
PL2144626T3 (pl) 2015-09-30
EP2144626B1 (en) 2014-12-03
HUE024427T2 (en) 2016-01-28
CA2682870A1 (en) 2008-10-23
CY1117290T1 (el) 2017-04-26
AU2008240181A1 (en) 2008-10-23
CA2682870C (en) 2016-08-09
US9636391B2 (en) 2017-05-02
EP2144626B8 (en) 2015-02-18
HRP20150177T1 (hr) 2015-04-10
US20130273110A1 (en) 2013-10-17
WO2008128065A2 (en) 2008-10-23
JP2010523711A (ja) 2010-07-15
WO2008128065A3 (en) 2008-12-18
US8932608B2 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
ES2531018T3 (es) Vacuna contra la tuberculosis y método de uso de la misma
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
BRPI1006452A2 (pt) vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
CR10291A (es) Vacuna de mycoplasma hyopneumoniae
ES2597832T3 (es) Vacuna acelular contra la tosferina
PE20061398A1 (es) Vacuna de toxoide de c. perfringens alfa
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
BRPI0712171A8 (pt) Método para formatar um gráfico e sistema para modificar um gráfico
CL2012000026A1 (es) Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
BRPI0713150A8 (pt) Regime em multidoses de vacinação de influenza poupador de adjuvante
CL2011000382A1 (es) Uso de una composicion inmunogenica que comprende una cantidad eficaz de un virus de sindrome disgenesico y respiratorio porcino (prrs) tipo ii para disminuir la incidencia, gravedad o prevenir los efectos de una enfermedad con fiebre alta de prrs.
CU23759A3 (es) Composiciones inmunogénicas
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
MX2016007726A (es) Inmunoterapia de cancer mediante el suministro de antigenos mhc clase ii usando un replicon de vlp.
CL2012002246A1 (es) Proceso para producir un extracto de alergenos; extracto de alergenos; uso de un extracto de alergenos para tratar alergia a los cacahuetes; composicion farmacéutica que comprende dicho extracto; vacuna que comprende un extracto de alergenos.
CO2025007834A2 (es) Composiciones inmunogénicas y métodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile
PE20140013A1 (es) Teobromina en combinacion con un expectorante o un mucolitico para su uso en terapia
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
AR039986A1 (es) Metodo para reducir el dolor usando virus oncoliticos